杨晶, 陈亚强, 门满库, 马园, 邵丽杰, 李欣. 胺碘酮联合艾司洛尔在射血分数中间值心力衰竭患者中治疗室性心律失常临床研究[J]. 心脏杂志, 2020, 32(3): 262-266. DOI: 10.12125/j.chj.202003017
    引用本文: 杨晶, 陈亚强, 门满库, 马园, 邵丽杰, 李欣. 胺碘酮联合艾司洛尔在射血分数中间值心力衰竭患者中治疗室性心律失常临床研究[J]. 心脏杂志, 2020, 32(3): 262-266. DOI: 10.12125/j.chj.202003017
    Jing YANG, Ya-qiang CHEN, Man-ku MEN, Yuan MA, Li-jie SHAO, Xin LI. Clinical study of amiodarone combined with esmolol in treatment of ventricular arrhythmia with heart failure with midrange ejection fraction[J]. Chinese Heart Journal, 2020, 32(3): 262-266. DOI: 10.12125/j.chj.202003017
    Citation: Jing YANG, Ya-qiang CHEN, Man-ku MEN, Yuan MA, Li-jie SHAO, Xin LI. Clinical study of amiodarone combined with esmolol in treatment of ventricular arrhythmia with heart failure with midrange ejection fraction[J]. Chinese Heart Journal, 2020, 32(3): 262-266. DOI: 10.12125/j.chj.202003017

    胺碘酮联合艾司洛尔在射血分数中间值心力衰竭患者中治疗室性心律失常临床研究

    Clinical study of amiodarone combined with esmolol in treatment of ventricular arrhythmia with heart failure with midrange ejection fraction

    • 摘要:
        目的  观察胺碘酮联合艾司洛尔在射血分数中间值心力衰竭(HFmrEF)患者中治疗室性心律失常的效果。
        方法  选取2018年1月至2020年1月收治的并发有HFmrEF的室性心律失常患者110例,随机分为两组,每组55例。胺碘酮组在抗心衰治疗同时给予口服胺碘酮治疗,联合组在胺碘酮组基础上联合给予静脉艾司洛尔治疗。对比两组用药前后疗效、收缩压(SBP)、舒张压(DBP)、心率、左室收缩末期容积(LVESV)、左室舒张末期容积(LVEDV)、左室射血分数(LVEF)及不良反应。
        结果  治疗48 h后两组SBP、DBP及心率均显著低于本组治疗前(P<0.05),且联合组显著低于胺碘酮组(P<0.05)。治疗4周后联合组显著有效率及总有效率均显著高于胺碘酮组(P<0.01)。4周后两组患者的LVEDV、LVESV及LVEF水平与本组治疗前相比,均无显著性差异;且联合组与胺碘酮组之间差异亦无统计学意义。两组不良反应发生率比较差异无统计学意义。
        结论  胺碘酮联合艾司洛尔可有效治疗HFmrEF患者的室性心律失常且安全性较好,但对心功能无明显改善作用。

       

      Abstract:
        AIM  To observe the clinical effect of amiodarone combined with esmolol in the treatment of ventricular arrhythmia in midrange ejection fraction heart failure (HFmrEF).
        METHODS  One hundred and ten cases of ventricular arrhythmia with HFmrEF were admitted to our hospital from January 2018 to January 2020 and they were randomly divided into amiodarone group and combined group, with 55 cases in each group. Amiodarone group was treated with oral amiodarone tablets on the base of corrective heart failure treatment, while combined group was treated with esmolol injection on the base of amiodarone group. The therapeutic effect, systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV) and the incidence of adverse reactions were compared between the two groups before and after medication.
        RESULTS  After 48-hour treatment, SBP, DBP and heart rate of the two groups were lower than those before treatment (P<0.05), and those in combined group were lower than those in amiodarone group (P<0.05). After 4-week treatment, the significant effective rate and total effective rate in combined group were higher than those in amiodarone group (P<0.01). The levels of LVESV, LVEDV and LVEF in two groups after 4 weeks’ treatment were not significant different from those before treatment (P<0.05), and there was no statistical difference between the combined group and the amiodarone group. There was no significant difference in the incidence of adverse reactions between the two groups.
        CONCLUSION  Amiodarone combined with esmolol can effectively treat ventricular arrhythmia in HFmrEF patients with better safety,but there was no significant improvement in cardiac function.

       

    /

    返回文章
    返回